<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; data</title>
	<atom:link href="http://www.tapanray.in/tag/data/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Data Exclusivity in India: Innovation Catalyst or Affordability Risk for Indian Pharma?</title>
		<link>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma</link>
		<comments>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 06 Dec 2025 14:33:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11008</guid>
		<description><![CDATA[For over four decades, India’s pharmaceutical industry has been built on a powerful moral and economic proposition: that life-saving medicines should be affordable, accessible, and globally available from Indian manufacturing prowess. This principle transformed India into the “pharmacy of the developing &#8230; <a href="http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Push for Affordable Mental Health Meds: Triumphs and Challenges in 2025</title>
		<link>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025</link>
		<comments>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/#comments</comments>
		<pubDate>Sun, 03 Aug 2025 07:02:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[achievements]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Ghana]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[triumph]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10951</guid>
		<description><![CDATA[In June 2025, a small clinic in rural Ghana celebrated a milestone: it provided affordable antidepressants to 500 patients, thanks to India’s generic sertraline, costing just $2 a month per person. This was unimaginable a decade ago, when branded versions &#8230; <a href="http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging Data Science To Deliver Unique Patient-experience</title>
		<link>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-data-science-to-deliver-unique-patient-experience</link>
		<comments>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/#comments</comments>
		<pubDate>Mon, 24 Oct 2022 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[characteristics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[real.world]]></category>
		<category><![CDATA[RWD]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10719</guid>
		<description><![CDATA[“Changes in consumer behavior, many of which were accelerated by the COVID-19 pandemic, are fueling a redesign of the health ecosystem.” This finding was revealed by a recent study of the PwC’s Health Research Institute (HRI). The research provided insights about how &#8230; <a href="http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Have And Haven’t Changed In Pharma’s New Normal?</title>
		<link>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-have-and-havent-changed-in-pharmas-new-normal</link>
		<comments>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/#comments</comments>
		<pubDate>Sun, 26 Sep 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Aduhelm]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[augmenting]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changed]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hits]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misses]]></category>
		<category><![CDATA[modeling]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trends]]></category>
		<category><![CDATA[triggered]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10588</guid>
		<description><![CDATA[While navigating through the challenge of disruptive changes, several pharma marketers are now focusing more on creating, connecting, and leveraging all market and customer related data, across the organization. Astute ones are using state-of-the-art tools, platforms, and techniques to gain &#8230; <a href="http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Digital Initiatives In India: A Missing Link</title>
		<link>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-digital-initiatives-in-india-a-missing-link</link>
		<comments>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/#comments</comments>
		<pubDate>Mon, 05 Jul 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EHR]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IGHI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[NDHM]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[providers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[record]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10543</guid>
		<description><![CDATA[An interesting study &#8211; designed to investigate the challenges that Health and Human Services (HHS) organizations face in implementing digital and data solutions, stands out today &#8211; for many reasons. One such being, this ‘multi-country survey’ project team had no &#8230; <a href="http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Integrity Issue Haunts Again With Covid Vaccine?</title>
		<link>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-integrity-issue-haunts-again-with-covid-vaccine</link>
		<comments>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/#comments</comments>
		<pubDate>Mon, 29 Mar 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[haunts. AstraZeneca]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10454</guid>
		<description><![CDATA[On March 22, 2021, by a media release, AstraZeneca announced that its ‘US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% in preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.’ Quite unexpectedly, on March &#8230; <a href="http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time To Audit Pharma’s Doctor-Engagement And Other Digital Strategies</title>
		<link>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies</link>
		<comments>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/#comments</comments>
		<pubDate>Mon, 25 Jan 2021 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[audit]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[e-visits]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[format]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value-delivery]]></category>
		<category><![CDATA[walk the talk]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10400</guid>
		<description><![CDATA[It’s now over a year since the unprecedented global health crisis commenced. In this grueling saga, a silver lining is also visible. It helped pharma industry gain a fascinating operational experience, while navigating through disruptive business changes. The changes in the &#8230; <a href="http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Restart Pharma Demand Generation Activities With Actionable Insight</title>
		<link>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=restart-pharma-demand-generation-activities-with-actionable-insight</link>
		<comments>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/#comments</comments>
		<pubDate>Mon, 01 Jun 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Insishr]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10107</guid>
		<description><![CDATA[As the ‘Lockdown. 04’ in India passes by, a time comes to press the restart button of all business activities in the country, in a calibrated manner, though, keeping in mind, the Covid-19 cases is yet to find its peak &#8230; <a href="http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
